From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Test your knowledge on COVID-19 and DLBCL

Last Updated: Friday, October 15, 2021

 Fast Facts #6: COVID-19 and DLBCL

Loading...
Advertisement
News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management

Leukemia

Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study

OncoImmunology

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

Cancers

Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Blood Advances

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Annals of Medicine

Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Clinical Lymphoma, Myeloma & Leukemia

Updated results from a rapcabtagene autoleucel (YTB323) phase I study demonstrate durable efficacy and a manageable safety profile in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Advertisement
Advertisement